ArticleJournal of cosmetic dermatology2025
Impact of Vaginal Carbon Dioxide Laser Therapy Alone Versus Its Combination With Oral Bioactive Collagen Peptides, Ultra-Low Molecular Weight Hyaluronic Acid, and Other Functional Components on the Genitourinary Syndrome of Menopause: A Cohort Pilot Study in Italy.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Vaginal Carbon Dioxide Laser Therapy Alone Versus Its Combination With Oral Bioactive Collagen Peptides, Ultra-Low Molecular Weight Hyaluronic Acid, and Other Functional Components on the Genitourinary Syndrome of Menopause: A Cohort Pilot Study in Italy.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGenitourinary syndrome of menopause (GSM) includes clinical manifestations attributed to estrogen deficiency affecting the genitourinary tract of postmenopausal women. Treatment may require a multifaceted approach, including patient education, lifestyle modifications, physical, as well as hormonal and non-hormonal therapies.
aimsTo evaluate the efficacy and tolerability of vaginal CO PATIENTS/
methodsTwenty postmenopausal women with GSM were divided into two groups. Group 1 (n = 10) underwent three sessions of vaginal CO
resultsBoth groups showed improvements in VHI, pain scores, and FSFI, with Group 2 displaying more significant gains. Compared to Group 1, Group 2 had greater median differences in VHI (Δ = 11.00 vs. Δ = 8.50, p = 0.005) and VAS (Δ = -7.00 vs. Δ = -5.50, p = 0.017). Similarly, FSFI scores increased meaningfully in both groups, more so in Group 2 (from 53.50 to 67.50, p = 0.005 vs. from 51.50 to 60.50, p = 0.014 in Group 1). Treatment satisfaction was also higher in Group 2 (p = 0.047).
conclusionsThe addition of oral supplementation with BCP and other functional components to vaginal CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.